Anti-Hu limbic encephalitis preceding the appearance of mediastinal germinoma by 9 years

Matthew Silsby, MBBS (Hons), FRACP, Candice J. Clarke, BSc (Hons), MSc (MBT), MBA, Kenneth Lee, MBchB, FRCPA, and David Sharpe, MRCP(UK), FRACP

Neurol Neuroimmunol Neuroinflamm 2020;7:e685. doi:10.1212/NXI.0000000000000685

Autoimmune limbic encephalitis is characterized by the subacute onset of seizures, short-term memory loss, and confusion and can have a paraneoplastic or nonparaneoplastic etiology.1 Anti-Hu limbic encephalitis is typically paraneoplastic, most frequently associated with small-cell lung cancer.2 We report the case of a 28-year-old man diagnosed with a mediastinal germ cell tumor 9 years after presenting with anti-Hu-positive limbic encephalitis.

Case report

A 19-year-old man presented after a generalized tonic-clonic seizure after several days of headaches and confusion. He had no medical history and did not take regular medications. There was no history of drug use, and he was a nonsmoker. There was no focal neurologic deficit on examination.

Electroencephalography demonstrated right temporal spike and slow wave activity. Brain MRI showed hyperintensity in the right medial temporal lobe on T2 FLAIR sequence, without gadolinium enhancement (figure, A). CSF showed 3 monocytes, and the protein level was slightly elevated (0.48 g/L, NR 0.15–0.45 g/L). He was diagnosed with viral encephalitis.

At the age of 21 years, he re-presented with seizures, confusion, emotional lability, night sweats, and short-term memory loss. MRI demonstrated ongoing T2 FLAIR hyperintensity in the right medial temporal lobe. Further workup revealed serum anti-Hu antibodies by immunofluorescence (Inova Diagnostics, CA), confirmed by line immunoblot (Euroimmun Lubeck, Germany). Other antibodies, including amphiphostin, CRMP5, Ma2, Yo, Ri, titin, recoverin, SOX-1, and VGKC, were negative. He was diagnosed with paraneoplastic limbic encephalitis as per the guidelines by Graus.1

The CT scan of chest, abdomen, and pelvis was negative for malignancy, and whole-body PET was normal. Ultrasound revealed microcalcifications in the right testis. Alfa-fetoprotein and β-human chorionic gonadotropin (β-hCG) were negative.

He was managed with IV cyclophosphamide 0.75 g/m² monthly for 6 months as per the National Institute of Health (NIH) protocol, IV methylprednisolone 1000 mg daily for 5 days, and IV immunoglobulin (IVIG) 0.4 g/kg/d for 5 days. This was followed by oral prednisone 50 mg daily, weaned to 10 mg daily after several weeks, azathioprine 50 mg twice daily (1.33 mg/kg/d), IVIG 0.4 g/kg 1 day per month, and antiepileptic therapy.

His condition followed a fluctuating course, and repeated malignancy screening remained negative. Right orchectomy was performed at the age of 24 years; however, findings were nonspecific and his condition remained unchanged. At the age of 26 years, a single course of rituximab 1000 mg was given in response to radiologic relapse, after which neuropsychometric parameters and MRI mildly improved. Azathioprine and IVIG continued throughout; prednisone was ceased after a slow wean over 3 years.
At the age of 28 years, he re-presented with pleuritic chest pain. CT scan demonstrated a large anterior mediastinal soft-tissue lesion measuring 107 mm, which was highly glucose avid on PET (figure, B and C). Biopsy revealed a nonseminomatous germ cell tumor. Serum alfa-fetoprotein was 954 kIU/L (NR 0–6), and serum β-hCG 19 IU/L (NR 0–5). Serum anti-Hu remained positive, and all other antibodies remained negative.

Immunotherapy was ceased, and he received bleomycin, etoposide, and cisplatin (BEP) 2 months before surgical resection. Pathologic assessment showed a mixed germ cell tumor with low grade sarcomatous components. Immunohistochemistry was performed on permeabilized formalin-fixed paraffin-embedded tissue with HuD antibody at a dilution of 1:100 on an automated Leica Bond III. Tumor tissue was compared with normal brain as a positive control; however, it did not stain positive.

He has been neurologically stable for 3 years postoperatively and has now been able to undertake a vocational training course. He is no longer receiving immunotherapy. Lung recurrences 6 months and 2 years postoperatively required repeat resection and chemoradiotherapy. Neurologic PET, 11 months postoperatively, demonstrated resolution of previously persistent temporal lobe changes (figure, D).

Discussion

Our patient presented with paraneoplastic limbic encephalitis, presumably since the age of 19 years. However, it was not until 9 years later that malignancy was detected. Paraneoplastic limbic encephalitis frequently precedes the diagnosis of an underlying malignancy; however, the current criteria for diagnosis include demonstration of malignancy within 4[2] or 5[1] years.

Anti-Hu antibodies are associated with malignancy in more than 95% of cases, so the eventual detection of malignancy as in our case should not be surprising. It is more typical that Hu antibodies are associated with small-cell lung cancer, although a mediastinal germinoma has been reported.[4] It is possible that testicular microcalcifications were evidence of earlier immunologic activity, especially given the development of a germ cell tumor.

This very long delay between Hu antibody positivity and the diagnosis of malignancy is atypical. Similar cases include detection of small-cell lung cancer 5.5 years after anti-Hu-associated subacute sensory neuronopathy,[5] lung carcinoid detected 8 years after initial diagnosis of anti-Ri antibodies,[6] and 2 patients in whom malignancy developed 4.5 and 10 years, respectively, after detection of anti-Yo antibody-associated cerebellar degeneration.[7]
Although our patient’s tumor did not stain positive for anti-Hu, it was likely responsible for his syndrome, as evidenced by his improvement after resection. Negative staining might be explained by preanalytical fixation of the tissue influencing the binding capacity of the antibody or a lack of specificity to particular epitopes on the tumor itself.

The long delay between the detection of anti-Hu antibodies and the diagnosis of malignancy in this case highlights the importance of ongoing surveillance for malignancy in the presence of onconeuronal antibodies.

**Study Funding**
No targeted funding reported.

**Disclosure**
The authors report no disclosures. Go to Neurology.org/NN for full disclosures.

**Publication history**

**Appendix Authors**

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Role</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Silsby, MBBS</td>
<td>Neurology Department Concord</td>
<td>Author</td>
<td>Design and conceptualized study; patient management; drafted manuscript, edited and approved final draft</td>
</tr>
<tr>
<td>(Hons), FRACP</td>
<td>Repatriation General Hospital, Sydney, Australia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Candice J. Clarke, BSc (Hons), MSc (MBT), MBA</td>
<td>Anatomical Pathology Department Concord Repatriation General Hospital, Sydney, Australia</td>
<td>Author</td>
<td>Interpreted pathologic data, revised the manuscript for intellectual content, edited and approved final draft</td>
</tr>
<tr>
<td>Kenneth Lee, MBChB, FRCPA</td>
<td>Anatomical Pathology Department Concord Repatriation General Hospital, Sydney, Australia</td>
<td>Author</td>
<td>Interpreted pathologic data, revised the manuscript for intellectual content, edited and approved final draft</td>
</tr>
<tr>
<td>David Sharpe, MRCP(UK), FRACP</td>
<td>Neurology Department Concord Repatriation General Hospital, Sydney, Australia</td>
<td>Author</td>
<td>Design and conceptualized study; patient management; drafted manuscript, edited and approved final draft</td>
</tr>
</tbody>
</table>

**References**
Anti-Hu limbic encephalitis preceding the appearance of mediastinal germinoma by 9 years
*Neurol Neuroimmunol Neuroinflamm* 2020;7;
DOI 10.1212/NXI.0000000000000685

This information is current as of February 21, 2020

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://nn.neurology.org/content/7/3/e685.full.html">http://nn.neurology.org/content/7/3/e685.full.html</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>References</td>
<td>This article cites 7 articles, 1 of which you can access for free at: <a href="http://nn.neurology.org/content/7/3/e685.full.html##ref-list-1">http://nn.neurology.org/content/7/3/e685.full.html##ref-list-1</a></td>
</tr>
<tr>
<td>Subspecialty Collections</td>
<td>This article, along with others on similar topics, appears in the following collection(s):</td>
</tr>
<tr>
<td></td>
<td><em>Autoimmune diseases</em> <a href="http://nn.neurology.org//cgi/collection/autoimmune_diseases">http://nn.neurology.org//cgi/collection/autoimmune_diseases</a></td>
</tr>
<tr>
<td></td>
<td><em>Paraneoplastic syndrome</em> <a href="http://nn.neurology.org//cgi/collection/paraneoplastic_syndrome">http://nn.neurology.org//cgi/collection/paraneoplastic_syndrome</a></td>
</tr>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://nn.neurology.org/misc/about.xhtml#permissions">http://nn.neurology.org/misc/about.xhtml#permissions</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: <a href="http://nn.neurology.org/misc/addir.xhtml#reprintsus">http://nn.neurology.org/misc/addir.xhtml#reprintsus</a></td>
</tr>
</tbody>
</table>